RA
DPLO

Royce & Associates’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Royce & Associates’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-389,595
Closed -$5.24M – 1212
2018
Q4 		$5.24M Buy
+389,595
New +$6.57M 0.05% 490

Other funds holding DPLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Royce & Associates's DPLO Position: Q1 2019 in Review

Royce & Associates sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2019, closing a stake of 389,595 shares — an estimated $5.24M sold.

Royce & Associates first reported a position in DPLO in Q4 2018 and held it in 1 quarter. The position peaked at $5.24M in Q4 2018. 150 funds tracked by Wall St. Rank hold DPLO as of Q1 2019.

  • Royce & Associates reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2019 after selling out during the quarter.
  • Royce & Associates sold 389,595 DIPLOMAT PHARMACY, INC. shares in Q1 2019, an estimated $5.24M.
  • Royce & Associates first reported a position in DIPLOMAT PHARMACY, INC. in Q4 2018 and held it in 1 quarter.
  • Royce & Associates's DIPLOMAT PHARMACY, INC. position peaked at $5.24M in Q4 2018.
  • 150 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2019.

Based on Royce & Associates's 13F filing for Q1 2019, filed 9 May 2019.